<DOC>
	<DOCNO>NCT00316940</DOCNO>
	<brief_summary>RATIONALE : Radioactive substance , samarium 153 , may release radiation break kill cancer cell . Bortezomib may stop growth cancer cell block enzymes need cell growth . Bortezomib may also make tumor cell sensitive radiation . Giving samarium 153 together bortezomib may kill cancer cell . PURPOSE : This phase I trial study side effect best dose samarium 153 give together bortezomib treat patient relapsed refractory multiple myeloma .</brief_summary>
	<brief_title>Samarium 153 Bortezomib Treating Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess safety tolerability ( maximum tolerate dose dose-limiting toxicity ) samarium Sm 153 lexidronam pentasodium bortezomib patient relapse refractory multiple myeloma . Secondary - Determine response rate ( combined complete response , partial response , minimal response ) patient treat regimen . - Determine time response time progression disease patient treat regimen . - Determine progression-free survival overall survival patient treat regimen . - Assess antitumor effect regimen patient . OUTLINE : This open-label , dose-escalation study samarium Sm 153 lexidronam pentasodium . Patients receive bortezomib IV 3-5 second day 1 , 4 , 8 , 11 samarium Sm 153 lexidronam pentasodium IV day 3 . Treatment repeat every 8 week 4 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos samarium Sm 153 lexidronam pentasodium maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . The MTD samarium Sm 153 lexidronam pentasodium determine 2 different dos bortezomib . After completion study treatment , patient follow every 3 month . PROJECTED ACCRUAL : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Samarium ethylenediaminetetramethylenephosphonate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosed multiple myeloma 1 follow criterion : Meets 2 follow major criterion : Plasmacytomas tissue biopsy Bone marrow plasmacytosis ( i.e. , &gt; 30 % plasma cell ) Monoclonal immunoglobulin spike IgG &gt; 3.5 g/dL IgA &gt; 2.0 g/dL serum electrophoresis ; kappa lambda light chain excretion &gt; 1 g 24hour urine protein electrophoresis Plasmacytomas tissue biopsy AND meet 1 follow minor criterion : Presence monoclonal immunoglobulin lesser magnitude give major criterion Lytic bone lesion Normal IgM &lt; 50 mg/dL , IgA &lt; 100 mg/dL , IgG &lt; 600 mg/dL Monoclonal immunoglobulin spike IgG &gt; 3.5 g/dL IgA &gt; 2.0 g/dL serum electrophoresis ; kappa lambda light chain excretion &gt; 1 g 24hour urine protein electrophoresis AND meet 1 follow minor criterion : Bone marrow plasmacytosis ( i.e. , 1030 % plasma cell ) Lytic bone lesion Presence monoclonal immunoglobulin lesser magnitude give major criterion bone marrow plasmacytosis ( i.e. , 1030 % plasma cell ) AND meet 1 follow minor criterion : Lytic bone lesion Normal IgM &lt; 50 mg/dL , IgA &lt; 100 mg/dL , IgG &lt; 600 mg/dL Measurable disease , define monoclonal immunoglobulin spike ≥ 1 gm/dL serum electrophoresis and/or immunoglobulin spike ≥ 200 mg 24hour urine protein electrophoresis evidence lytic bone disease OR Nonmeasurable disease ( i.e. , patient nonsecretory oligosecretory multiple myeloma ) Relapsed refractory disease Relapsed disease follow response stable disease prior chemotherapy ( e.g. , singleagent steroid , vincristine , doxorubicin , dexamethasone [ VAD ] , melphalan prednisone [ MP ] ) highdose chemotherapy Refractory ( i.e. , failure achieve least complete partial response stable disease ) recent chemotherapy without systemic corticosteroid No plasma cell dyscrasia polyneuropathy , organomegaly , endocrinopathy , monoclonal protein ( Mprotein ) , skin change ( POEMS syndrome ) No extramedullary myeloma PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Life expectancy &gt; 3 month Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 75,000/mm³ AST ALT ≤ 3 time upper limit normal ( ULN ) Bilirubin ≤ 2 time ULN ( unless clearly related disease ) Creatinine clearance ≥ 30 mL/min Creatinine clearance &gt; 15 mL/min &lt; 30 mL/min due significant myelomatous involvement kidney allow discretion investigator Sodium &gt; 130 mmol/L No ECG evidence acute ischemia new conduction system abnormalities No myocardial infarction within past 6 month Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection No severe hypercalcemia ( i.e. , serum calcium ≥ 14 mg/dL ) No New York Hospital Association class III IV heart failure No poorly control hypertension , diabetes mellitus , serious medical psychiatric illness would preclude study treatment No know HIV history No known active hepatitis B C viral infection No history allergic reaction attributable compound similar chemical biological composition bortezomib , boron , mannitol , ethylenediaminetetramethylenephosphonic acid ( EDTMP ) , phosphonates No peripheral neuropathy &gt; grade 1 PRIOR CONCURRENT THERAPY : At least 12 week since prior samarium Sm 153 lexidronam pentasodium No 1 prior treatment At least 24 week since prior strontium chloride Sr 89 No 1 prior treatment No major surgery within past 4 week No chemotherapy within past 3 week ( 6 week nitrosoureas ) No corticosteroid ( &gt; 10 mg/day prednisone equivalent ) within past 3 week No immunotherapy , antibody therapy , radiotherapy ( except localize radiotherapy ) within past 4 week No concurrent investigational agent No concurrent corticosteroid ( ≥ 10 mg prednisone equivalent )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>